Diabetic peripheral neuropathy: An update on pathogenesis and management

Current Neurology and Neuroscience Reports

Volumn 6, Issue 1, 2006, Pages 1-4

  Gundogdu, Betul M ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; ANTICONVULSIVE AGENT; AS 3021; BRAIN DERIVED NEUROTROPHIC FACTOR; C PEPTIDE; CAPSAICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; EPALRESTAT; FIDARESTAT; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; MEXILETINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; OPIATE; PLACEBO; PREGABALIN; PROSTAGLANDIN DERIVATIVE; RECOMBINANT NERVE GROWTH FACTOR; RUBOXISTAURIN; THIOCTIC ACID; TRAMADOL; TRANDOLAPRIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASODILATOR AGENT;

AUTOIMMUNITY; AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST OF ILLNESS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; EARLY DIAGNOSIS; GENE TRANSFER; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MORBIDITY; MORTALITY; NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; HUMANS;

EID: 31544481862     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-996-0001-3     Document Type: Note

References (38)

1. Pirart J: Diabetes mellitus and its degenerative complications. A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978, 1:168-188.
2. Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817-824.
3. Partanen J, Niskanen L, Lehtinen J, et al.: Natural history of peripheral neuropathy in patients with non-insulin-dependant diabetes mellitus. N Engl J Med 1995, 333:89-94.
4. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988, 11:592-597.
5. Cohen JA, Jeffers BW, Faldut D, et al.: Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependant diabetes mellitus (NIDDM). Muscle Nerve 1998, 21:72-80.
6. Ziegler D: Polyneuropathy in the diabetic patient - update on pathogenesis and management. Nephrol Dial Transplant 2004, 19:2170-2175.
7. Low PA, Benrud-Larson LM, Sletten DM, et al.: Autonomic symptoms and diabetic neuropathy. A population based study. Diabetes Care 1992, 12:2942-2947.
8. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on nerve conduction in the Diabetes control and Complications Trial. Ann Neurol 1995, 38:869-880.
9. Singleton JR, Smith AG, Russell JW, Feldman EL: Polyneuropathy with impaired glucose tolerance: Implications for diagnosis and therapy. Curr Opin Neurol 2005, 7:33-42.
10. Vincent AM, Russell JW, Low P, Feldman EL: Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Rev 2001, 25:612-628.
11. Russell JW, Golovoy D, Vincent AM, et al.: High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002, 16:1738-1748.
12. Uemura S, Matsushita H, Li W, et al.: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001, 88:1291-1298.
13. Tyagi SC, Hayden MR: Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Failure Rev 2003, 8:23-28.
14. Giannini C, Dyck PJ: Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995, 37:498-504.
15. Siperstein MD, Norton W, Unger RH, Madison LL: Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Phys 1966, 79:330-347.
16. Tesfaye S, Chaturvedi N, Eaton SE, et al., for the EURODIAB Prospective Complications Study Group: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
17. Sharma K, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758-765.
18. Vinik AI: Neuropathy: New concepts in evaluation and treatment. South Med J 2002, 95:21-23.
19. Dyck PJ, Windebank AJ: Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002, 25:477-491.
20. Leinninger GM, Vincent AM, Feldman EL: The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004, 9:26-53.
21. Sima AA, Cherian PV. Neuropathology of diabetic neuropathy and its correlations with neurophysiology. Clin Neurosci 1997, 4:359-364.
22. Terasima T, Kojima H, Fujiyama M, et al.: The fusion of bone marrow derived proinsulin expressing cells with nerve cells underlies diabetic neuropathy. Proc Natl Acad Sci U S A 2005, 102:12525-12530.
23. Boulton AJ, Vinik AI, Arezzo JC, et al.: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
24. Arezzo J, Hohman T, Porte D, Raskin P, for the Fidarestat Investigators: Phase II investigation of fidarestat in patients with diabetic polyneuropathy. J Peripher Nerv Syst 2003, 8:189.
25. Bril V, Buchanan RA: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004, 27:2369-2375.
26. Ziegler D, Nowak H, Kempler P, et al.: Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant-lipoic acid: a meta-analysis. Diabetic Med 2004, 21:114-121.
27. Schratzberger P, Walter DH, Rittig K, et al.: Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001, 107:1083-1092.
28. Simovic D, Isner JM, Ropper AH, et al.: Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001, 58:761-768.
29. Malik RA, Williamson S, Abbott C, et al.: Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double blind placebo controlled trial. Lancet 1998, 352:1978-1981.
30. Apfel SC, Schwartz S, Adornato BT, et al.: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000, 284:2215-2221.
31. Wellmer A, Misra VP, Sharief MK, et al.: A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001, 6:204-210.
32. Bastyr EJ III, Price KL, Skljarevski V, et al.: Ruboxistaurin (RBX) mesylate treatment in patients with diabetic peripheral neuropathy (DPN) improves clinical global impression (CGI) and correlates with change in patient-positive sensory symptoms and neurological signs. J Peripher Nerv Syst 2003, 8:190.
33. Ekberg K, Brismar T, Johansson BL, et al.: Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003, 52:536-541.
34. Jarvis B, Coukell AJ: Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998, 56:691-707.
35. Harati Y, Gooch C, Swenson M: Double-blind randomized trial of tramadol for the treatment of pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
36. Forst T, Pohlmann T, Kunt T: The influence of local capsaicin treatment on small nerve fiber function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002, 39:1-6.
37. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2002, 110:628-638.
38. Wernicke J, Rosen AS, Lu Y, et al.: Superiority of duloxetine over placebo in the treatment of diabetic neuropathic pain demonstrated in two studies [abstract]. Diabetes 2004, 53(Suppl 2):A24.